Clinical trial
A Phase 1b, Open-label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of AK0529 in Infants Hospitalized With Respiratory Syncytial Virus Infection
NCT02460016 is registered in ClinicalTrials.gov with Shanghai Ark Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Open-label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of AK0529 in Infants Hospitalized With Respiratory Syncytial Virus Infection
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- August 28, 2015
- Completion date
- November 3, 2015
- Enrollment
- 1 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.